NexImmune, Inc.
NEXI evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $139
- Lead Asset:
- nexi-001 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for NEXI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$139
Cash Runway
—
Lead Asset
nexi-001 (Phase 2)
Next Catalyst
—
Tracking 3 pipeline candidates for NexImmune, Inc..
Run NexImmune, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NexImmune, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 21, 2026- % of float
- 1.3%
- Days to cover
- 2.3
- Shares short
- 15,988
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NEXI short interestGovernance
Frequently asked questions
What is NexImmune, Inc.'s lead drug candidate?
NexImmune, Inc.'s most advanced tracked candidate is nexi-001 (Phase 2) for Acute myeloid leukemia (AML) in patients who have relapsed post allo-stem cell transplant.
Who is the CEO of NexImmune, Inc.?
Series A Preferred Stock is the chief executive officer of NexImmune, Inc. (NEXI).
Where is NexImmune, Inc. headquartered?
NexImmune, Inc. (NEXI) is headquartered in Gaithersburg, MD, United States.
What therapeutic areas does NexImmune, Inc. focus on?
NexImmune, Inc. develops therapies across Oncology, Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.